-
Posted by
Two Blokes May 1 -
Filed in
Stock
-
3 views
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) reported progress across its research programmes and raised new funds during the 2024 financial year. The company advanced its lead programme GF-1002, targeting MASH, to the pre-IND stage.
